A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)-Reference-Cited by-同舟云学术

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

Published:2016-06-24 Issue:1 Volume:31 Page:107-114
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Hájek R,Masszi T,Petrucci M T,Palumbo A,Rosiñol L,Nagler A,Yong K L,Oriol A,Minarik J,Pour L,Dimopoulos M A,Maisnar V,Rossi D,Kasparu H,Van Droogenbroeck J,Yehuda D B,Hardan I,Jenner M,Calbecka M,Dávid M,de la Rubia J,Drach J,Gasztonyi Z,Górnik S,Leleu X,Munder M,Offidani M,Zojer N,Rajangam K,Chang Y-L,San-Miguel J F,Ludwig H

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2016176.pdf

Reference24 articles.

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.

2. Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004; 79: 867–874.

3. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149–157.

4. Durie BG, Moreau P, Sonneveld P, Morgan GJ, Lahuerta JJ, Beksac M et al. Regional differences in the treatment approaches for relapsed multiple myeloma: an IMF study. J Clin Oncol 2012; 30: 15s (abstract 8095).

5. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110: 3557–3560.

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiac Complications of Multiple Myeloma Treatments;Cardiology in Review;2024-09-10

2. Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab‐exposed relapsed/refractory multiple myeloma patients: A retrospective analysis;European Journal of Haematology;2024-08-26

3. LILRB4 regulates multiple myeloma development through STAT3-PFKFB1 pathway;Cell Death & Disease;2024-07-18

4. Target trial emulation of carfilzomib safety among patients with relapsed/refractory multiple myeloma using a nationwide observational data in Korea;Journal of Cancer Research and Clinical Oncology;2024-05-20

5. Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors;European Respiratory Journal;2024-05-02